Group 1: Company Developments - Xidi Intelligent Driving submitted its prospectus for the second time to the Hong Kong Stock Exchange, aiming for a main board listing, focusing on autonomous driving products and solutions for commercial vehicles [1] - Shandong Molong announced that its shareholder, Zhimo Holdings, reduced its H-shares by 28.81 million shares, accounting for 3.61% of the total share capital, following a significant increase in H-share prices [2] - Lide Education's controlling shareholders pledged a total of 4.97 million shares to secure a loan of 350 million yuan, indicating a need for additional funding to support business development [3][4] - Insilico Medicine submitted its listing application to the Hong Kong Stock Exchange for the third time, showing a commitment to enter the capital market, with steady revenue growth and narrowing losses [5] - Zhuangshi China projected a loss of approximately 385 million to 425 million HKD for the fiscal year ending March 31, 2025, primarily due to fair value losses on investment properties [6][7] Group 2: Financial Performance - Xidi Intelligent Driving reported revenues of 31.06 million yuan, 133 million yuan, and 410 million yuan for 2022, 2023, and 2024, respectively, with losses of approximately 263 million yuan, 255 million yuan, and 581 million yuan [1] - Insilico Medicine's revenues were 30.15 million USD, 51.18 million USD, and 85.83 million USD for 2022, 2023, and 2024, with losses of 222 million USD, 212 million USD, and 17.1 million USD [5] - Zhuangshi China reported a loss of approximately 321 million HKD in the previous year, with the current projected losses indicating a worsening financial situation [6]